Published in:
01-03-2018 | Research Letter
Intermittent administration of PTH induces the expression of osteocalcin and BMP-2 on choroid plexus cells associated with suppression of sclerostin, TGF-β1, and Na+K+ATPase
Authors:
Allan Fernando Giovanini, Isabella Göhringer, Rosangela Tavella, Manuelly Cristiny Linzmeyer, Thaynara Fernanda Priesnitz, Luana Mordask Bonetto, Rafaela Guimarães Resende, Rafaela Scariot, João Cesar Zielak
Published in:
Endocrine
|
Issue 3/2018
Login to get access
Excerpt
The parathyroid hormone (PTH) is a key hormone that acts on the regulation of calcium homeostasis and bone turnover. Despite evidence that this hormone has a dual action, for example, anabolic or catabolic effects, researchers have described that when the PTH is administrated in an intermittent form, it acts in favor of bone formation, which is why the Food and Drug Administration supports it for the treatment of osteoporosis [
1]. According to this premise, some experiments with model animals have reinforced the hypothesis that this therapeutic approach may be a likely alternative to induce osteoneogenesis in areas that have been lost due to trauma, intra bonny cysts, or neoplasia [
2]. …
